Analysts Set Expectations for AngioDynamics FY2026 Earnings

AngioDynamics, Inc. (NASDAQ:ANGO) – Stock analysts at Zacks Research lifted their FY2026 EPS estimates for shares of AngioDynamics in a research note issued to investors on Thursday, October 23rd. Zacks Research analyst Team now forecasts that the medical instruments supplier will post earnings of ($0.26) per share for the year, up from their previous forecast of ($0.30). The consensus estimate for AngioDynamics’ current full-year earnings is ($0.37) per share. Zacks Research also issued estimates for AngioDynamics’ Q4 2026 earnings at $0.02 EPS, Q1 2027 earnings at ($0.10) EPS, Q2 2027 earnings at ($0.04) EPS and FY2027 earnings at ($0.18) EPS.

AngioDynamics (NASDAQ:ANGO) last issued its earnings results on Thursday, October 2nd. The medical instruments supplier reported ($0.10) EPS for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.02. The business had revenue of $75.71 million during the quarter, compared to analysts’ expectations of $72.69 million. AngioDynamics had a negative net margin of 10.67% and a negative return on equity of 3.16%. The company’s quarterly revenue was up 12.1% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.11) earnings per share. AngioDynamics has set its FY 2026 guidance at -0.330–0.230 EPS.

Several other brokerages have also recently weighed in on ANGO. Canaccord Genuity Group boosted their target price on AngioDynamics from $17.00 to $18.00 and gave the stock a “buy” rating in a report on Friday, October 3rd. Lake Street Capital initiated coverage on AngioDynamics in a research note on Wednesday, July 16th. They set a “buy” rating and a $24.00 price objective on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of AngioDynamics in a report on Wednesday, October 8th. Wall Street Zen lowered AngioDynamics from a “buy” rating to a “hold” rating in a report on Saturday, October 4th. Finally, HC Wainwright reissued a “buy” rating and set a $16.00 price target on shares of AngioDynamics in a research report on Wednesday, July 16th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, AngioDynamics presently has an average rating of “Moderate Buy” and an average price target of $19.33.

AngioDynamics Trading Down 0.4%

Shares of NASDAQ ANGO opened at $12.29 on Monday. The stock has a market cap of $506.35 million, a PE ratio of -15.76 and a beta of 0.78. AngioDynamics has a 12-month low of $6.57 and a 12-month high of $13.50. The company has a 50-day moving average of $10.85 and a 200 day moving average of $9.97.

Institutional Investors Weigh In On AngioDynamics

Institutional investors and hedge funds have recently made changes to their positions in the stock. GSA Capital Partners LLP purchased a new position in shares of AngioDynamics during the 1st quarter worth approximately $642,000. New York State Common Retirement Fund lifted its stake in AngioDynamics by 667.0% during the first quarter. New York State Common Retirement Fund now owns 54,635 shares of the medical instruments supplier’s stock worth $513,000 after purchasing an additional 47,512 shares in the last quarter. Phocas Financial Corp. purchased a new position in shares of AngioDynamics during the first quarter worth $3,177,000. Principal Financial Group Inc. boosted its position in shares of AngioDynamics by 25.1% during the first quarter. Principal Financial Group Inc. now owns 120,008 shares of the medical instruments supplier’s stock worth $1,127,000 after buying an additional 24,047 shares during the period. Finally, Cubist Systematic Strategies LLC grew its stake in shares of AngioDynamics by 71.8% in the first quarter. Cubist Systematic Strategies LLC now owns 232,473 shares of the medical instruments supplier’s stock valued at $2,183,000 after buying an additional 97,123 shares in the last quarter. 89.43% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at AngioDynamics

In other AngioDynamics news, SVP Lawrence T. Weiss purchased 10,000 shares of the stock in a transaction dated Tuesday, October 21st. The stock was acquired at an average cost of $11.81 per share, for a total transaction of $118,100.00. Following the acquisition, the senior vice president owned 93,597 shares in the company, valued at $1,105,380.57. This trade represents a 11.96% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO James C. Clemmer acquired 10,000 shares of the business’s stock in a transaction that occurred on Thursday, October 9th. The shares were acquired at an average cost of $11.15 per share, with a total value of $111,500.00. Following the completion of the transaction, the chief executive officer directly owned 882,529 shares in the company, valued at approximately $9,840,198.35. The trade was a 1.15% increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders bought 20,890 shares of company stock worth $239,532. Corporate insiders own 6.00% of the company’s stock.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.